ATEKA Tx brings to the pharma industry a new mode of action central to brain protection and function. Our molecules activate the couple BDNF-TrkB. BDNF deficiency is known to be the root cause of neurodegenerative diseases. BDNF is also necessary for axone and synapse plasticity.
15 years of research in prestigious French Universities has led to the discovery of the activity of small, patented molecules, on the BDNF-TrkB pathway. Many preclinical studies demonstrated the affinity and the positive modulation of BDNF in vitro and in vivo.
In a HD model of mice, our leads have shown the reduction of tremors, a kex symptom of the disease.
ATEKA Tx intends to perform regulatory pre-clinical studies necessary to test its lead in Amyotrophic Lateral Sclerosis. In parallel, ATEKA Tx will seek partnerships in a large panel of indications and also using its leads and back-up compounds.
ATEKA is seeking CROs specialised in CNS
ATEKA is open to discussions with Biotech and Pharma players in the CNS Areas, like degenerative or cognitive diseases